Brought to you by 
Corixa and GSK Biologicals enter new cancer vaccine deal
28 Jul 2003
Executive Summary
Corixa (immunotherapeutics) and GlaxoSmithKline Biologicals have completed the research phase of their deal on tumor vaccines and have signed a new agreement, shifting some development rights to Corixa.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Corixa and GSK Biologicals enter new cancer vaccine deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice